11 research outputs found
Newborn screening timeliness quality improvement initiative: Impact of national recommendations and data repository.
BackgroundNewborn screening (NBS) aims to achieve early identification and treatment of affected infants prior to onset of symptoms. The timely completion of each step (i.e., specimen collection, transport, testing, result reporting), is critical for early diagnosis. Goals developed by the Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) for NBS timeliness were adopted (time-critical results reported by five days of life, and non-time-critical results reported by day seven), and implemented into a multi-year quality improvement initiative (NewSTEPS 360) aimed to decrease the time to result reporting and intervention.MethodsThe NBS system from specimen collection through reporting of results was assessed (bloodspot specimen collection, specimen shipping, sample testing, and result reporting). Annual data from 25 participating NBS programs were analyzed; the medians (and interquartile range, IQR) of state-specific percent of specimens that met the goal are presented.ResultsThe percent of specimens collected before 48 hours of life increased from 95% (88-97%) in 2016 to 97% (IQR 92-98%) in 2018 for the 25 states, with 20 (80%) of programs collecting more than 90% of the specimens within 48 hours of birth. Approximately 41% (IQR 29-57%) of specimens were transported within one day of collection. Time-critical result reporting in the first five days of life improved from 49% (IQR 26-74%) in 2016 to 64% (42%-71%) in 2018, and for non-time critical results from 64% (IQR 58%-78%) in 2016 to 81% (IQR 68-91%) in 2018. Laboratories open seven days a week in 2018 reported 95% of time-critical results within five days, compared to those open six days (62%), and five days (45%).ConclusionNBS programs that participated in NewSTEPs 360 made great strides in improving timeliness; however, ongoing quality improvement efforts are needed in order to ensure all infants receive a timely diagnosis
Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project.
Purpose: To achieve clinical validation of cutoff values for newborn screening by tandem mass
215 spectrometry through a worldwide collaboration. Methods: Cumulative percentiles of amino
216 acids and acylcarnitines in dried blood spots of approximately 30 million normal newborns and
217 10,615 true positive cases are compared to assign clinical significance, which is achieved when
218 the median of a disease range is either >99%ile or <1%ile of the normal population. The cutoff
219 target ranges of analytes and ratios are then defined as the interval between the limits of the two
220 populations. When overlaps occur, adjustments are made to maximize sensitivity and specificity
221 taking in consideration all available factors. Results: As of December 1, 2010, 129 sites in 45
222 countries have uploaded to the project website a total of 23,970 percentile data points, 558,168
223 analyte results of 10,615 true positive cases with 64 conditions, and 5,088 cutoff values. The
224 average rate of submission of true positive cases between December 1, 2008 and December 1,
225 2010 was 4.7 cases per day (3,418 cases). This cumulative evidence generated 91 and 23 high
226 and low target cutoff ranges, respectively. The overall proportion of cutoff values within the
227 respective target range was 43% (2,176/5,088). Conclusions: An unprecedented level of
228 cooperation and collaboration has allowed the objective definition of cutoff target ranges for 114
229 markers applied to newborn screening of rare metabolic disorders. This set of data could be used
230 as baseline for monitoring of future performance